Healthcare / Medical DistributionBSE
$1127.00
-14.90 (-1.30%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-420.3M · quality 47.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$49.0B
P/E
42.7x
↑EV/EBITDA
19.6x
↑ROE
6.8%
↑Gross Margin
10.3%
↓Debt/Equity
0.40
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+26.0%
FCF CAGR
—
FCF margin
0.4%
FCF / Net income
0.25x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $65.91B · net income $1.15B · FCF $286.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $65.91B | $65.91B | $50.96B | $38.88B | $32.93B |
| Net Income | $1.15B | $1.15B | $948.2M | $391.1M | $-115.6M |
| EBITDA | $2.77B | $2.77B | $2.11B | $1.21B | $649.5M |
| EPS | — | — | 21.76 | 10.81 | -2.66 |
| Gross Margin | 10.3% | 10.3% | 9.5% | 8.2% | 7.9% |
| Operating Margin | 3.4% | 3.4% | 2.8% | 2.2% | 1.2% |
| Net Margin | 1.7% | 1.7% | 1.9% | 1.0% | -0.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.40 | 0.40 | 0.22 | 0.21 | 0.74 |
| Current Ratio | 1.58 | 1.58 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $286.6M | $286.6M | $-881.8M | $-420.3M | $-508.3M |
| Returns | |||||
| ROE | 6.8% | 6.8% | 5.5% | 2.4% | -1.9% |
| Valuation | |||||
| P/E | 42.72 | 42.72 | 54.16 | 92.95 | — |
| EV/EBITDA | 19.62 | 19.62 | 25.07 | 31.60 | — |
| P/B | 2.90 | 2.90 | 2.98 | 2.22 | — |
| Growth & Yield | |||||
| Revenue Growth | 29.3% | 29.3% | 31.1% | 18.1% | — |
| EPS Growth | — | — | 101.3% | 506.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.8%
Start / end P/E
n/dx → n/dx
EPS bridge
21.76 → n/d
Residual
-23.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.